Boston Scientific (BSX) Stock Today: Price Slips as Neuromodulation Bull Case, Epic EHR Deal and Big Fund Moves Shape the Outlook

Boston Scientific Corporation (NYSE: BSX) shares traded lower on Wednesday, November 19, 2025, even as a wave of fresh research, strategic partnership news and institutional ownership updates painted a largely constructive long‑term picture for the medtech giant.

BSX stock price on 19 November 2025

As of late Wednesday trading, Boston Scientific stock was changing hands at around $96.6, down roughly 2.6% on the day. Intraday, BSX has traded in a range of roughly $96–$100, with volume running in the high single‑digit millions of shares. ^[1]

Recent price action shows a short losing streak: BSX closed at about $99.2 on Tuesday (‑2.5%), $101.8 on Monday (‑0.9%), and has now given back a chunk of the gains it enjoyed after October’s strong earnings report. ^[2]

Despite today’s pullback, Boston Scientific remains toward the upper half of its 52‑week range, with a 12‑month low near $85.98 and a high around $109.50. At today’s price, the company carries a market cap of roughly $145–150 billion and trades at about 53x trailing earnings, according to MarketBeat data. ^[3]

Note: This article covers Boston Scientific stock (NYSE: BSX), not the Bermuda Stock Exchange index, which coincidentally uses the symbol BSX for its benchmark. ^[4]

1. Fresh neuromodulation bull case from Zacks

One of the most important headlines for BSX today comes from Zacks Investment Research, published via Nasdaq and Yahoo Finance under the title “BSX’s Neuromodulation Prospect Looks Strong: What’s Behind It?” on November 19, 2025. ^[5]

Key takeaways from that report:

Neuromodulation growth: Boston Scientific’s Neuromodulation business grew 9% year‑over‑year in Q3 2025, continuing a strong run driven by its Brain and Pain franchises. ^[6]
INTREPID data: Five‑year results from the INTREPID study showed sustained benefits from deep brain stimulation (DBS) in patients with moderate to advanced Parkinson’s disease, supporting continued adoption of the company’s DBS systems. ^[7]
Relievant (Intracept) impact: The acquisition of Relievant (completed in 2023) is driving high‑single‑digit to double‑digit growth in the pain franchise. Its Intracept intraosseous nerve ablation system for vertebrogenic pain is seeing strong uptake in the U.S., with a limited launch now underway in parts of Europe, the Middle East and Africa following CE mark approval. ^[8]
Nalu Medical deal: Boston Scientific has agreed to acquire the remaining stake in Nalu Medical for about $533 million upfront, which will add a peripheral nerve stimulation platform and expand the company’s neuromodulation footprint beyond spinal cord stimulation and DBS. ^[9]
Relative performance & valuation: Over the past 12 months, BSX shares are up about 10%, compared with a small decline for the broader medical‑products industry. The Zacks piece notes that Boston Scientific trades at a premium forward price‑to‑sales multiple (around 6.7x vs. ~3x for the peer group) but argues that its above‑industry growth and pipeline justify that premium. ^[10]
Rating: BSX carries a Zacks Rank #2 (Buy), reflecting positive earnings estimate revisions and the firm’s expectation of continued double‑digit organic growth. ^[11]

Why this matters for the stock

The neuromodulation update reinforces the idea that Boston Scientific is not just a mature stent and structural‑heart business: it is steadily building a multi‑leg growth story spanning chronic pain, DBS, and now peripheral nerve stimulation. That diversification can help offset cyclical pressures in other medtech categories and supports the bullish long‑term earnings trajectory embedded in current analyst estimates.

2. New Epic collaboration brings BSX deeper into digital cardiology

Another fresh development today is a new collaboration between Boston Scientific and Epic, one of the dominant electronic health record (EHR) vendors in the U.S. Healthcare trade outlet MassDevice reported that Boston Scientific (NYSE: BSX) announced a partnership with Epic to support cardiac diagnostic EHR services on November 19, 2025. ^[12]

While full details of the deal aren’t publicly available yet, the coverage indicates:

The collaboration centers on integrating Boston Scientific’s cardiac diagnostic offerings with Epic’s software, enabling cardiologists and other clinicians to access and manage diagnostic information directly within the EHR.
Epic’s Aura specialty diagnostics suite is designed to connect health systems to external diagnostic partners so that test orders and results flow seamlessly into Epic. Boston Scientific already appears on Epic lists of integrated diagnostic and results partners. ^[13]

Strategic significance

This kind of integration hits several important themes for Boston Scientific:

Workflow stickiness: When devices and diagnostics are deeply embedded in EHR workflows, it becomes harder for hospitals to switch vendors, improving customer retention.
Data & remote monitoring: Cardiac diagnostics and ambulatory monitoring are moving toward continuous, remote models. Tight EHR integration can make Boston Scientific solutions more attractive to health systems that want richer data and fewer manual steps.
Digital health positioning: Zacks’ broader industry outlook flagged AI and digital‑health integration as a key driver of future medtech value creation, shifting profit pools from hardware margins toward recurring, data‑driven services. ^[14]

In short, this Epic deal—though still thin on public details—lines up well with Boston Scientific’s strategy of pairing devices with connected, interoperable digital platforms, especially in cardiac care.

3. 13F filings: big holders reshuffle their BSX exposure

Today also brought a cluster of MarketBeat‑summarized 13F filings that show a mix of profit‑taking and incremental buying among institutional investors.

Artisan Partners trims, but still holds a major stake

Artisan Partners Limited Partnership reduced its Boston Scientific position by about 11.8% in Q2 2025, selling 1,141,087 shares.
After the sale, Artisan still holds 8,518,201 BSX shares, worth roughly $915 million, making BSX its 20th‑largest holding and representing about 0.57% of Boston Scientific’s shares outstanding. ^[15]

The article highlights that insiders have sold around 175,000 shares (~$17.7 million) over the past quarter, even as the company continues to beat earnings estimates and raise guidance. ^[16]

First American Trust FSB cuts exposure

First American Trust FSB cut its stake in BSX by 24.7%, selling 26,394 shares in Q2.
It now holds 80,671 shares worth about $8.7 million, according to its most recent filing. ^[17]

Avantax and Dorsey Wright add to positions

On the other side of the ledger:

Avantax Advisory Services Inc. increased its BSX holdings by 16.7% in Q2, adding 7,103 shares for a total of 49,719 shares valued at roughly $5.34 million. ^[18]
Dorsey Wright & Associates opened a new BSX position, purchasing 15,232 shares valued at around $1.64 million. ^[19]

Across these filings, MarketBeat notes that approximately 89% of Boston Scientific’s stock is held by institutional investors, underscoring continued broad support from large, long‑term owners even as some funds rebalance or lock in gains. ^[20]

Interpretation

Rather than signaling a wholesale shift in sentiment, today’s 13F headlines look more like portfolio rebalancing:

Large holders such as Artisan and First American have taken some profits after a strong multi‑quarter run.
Other managers, including Avantax and Dorsey Wright, have used weakness as an opportunity to add exposure.

For individual investors, the net message is that institutional ownership remains very high, but there’s active debate over near‑term valuation versus long‑term growth.

4. Fundamentals and guidance remain strong after Q3 beat

All of today’s commentary sits on top of a very robust Q3 2025 earnings print, released on October 22.

According to Boston Scientific’s own earnings recap and multiple earnings summaries: ^[21]

Net sales:$5.06–5.07 billion, up 20.3% year‑over‑year on a reported basis and 15.3% on an organic basis.
Segment performance:
- MedSurg delivered 7.6% organic growth.
- Cardiovascular posted 19.4% organic growth, powered by procedures such as electrophysiology, structural heart and coronary interventions.
Earnings: Adjusted EPS of $0.75, beating the $0.71 consensus and at the high end of guidance.
Outlook:
- Full‑year 2025 adjusted EPS guidance was raised to $3.02–$3.04.
- Q4 2025 guidance calls for organic revenue growth of 11–13% and EPS of $0.77–$0.79.

MarketBeat’s earnings summary also notes that Boston Scientific generated $19.35 billion in trailing 12‑month revenue and $1.85 billion in net income, with trailing EPS of $1.87 and an expected 13% earnings growth next year (to about $3.23 per share). ^[22]

The Zacks industry outlook published yesterday reinforces that story, describing Boston Scientific as entering 2026 with:

“Exceptional” organic growth of around 15%, particularly in electrophysiology (led by FARAPULSE) and left atrial appendage closure via WATCHMAN.
Margin expansion, thanks to favorable mix, cost discipline and pricing power, even amid an estimated $100 million tariff headwind.
A pipeline that includes AGENT drug‑coated balloon, FARAPOINT, OPAL HDx integration and WATCHMAN Elite, plus momentum in China and improving backorder trends after ERP issues. ^[23]

All of this underpins why many analysts are willing to look through near‑term share volatility.

5. How Wall Street values BSX after today’s drop

Even after today’s roughly 2.5–2.6% decline, Boston Scientific is not a “cheap” stock on traditional valuation metrics—but relative analyses suggest it may still offer upside.

Consensus price targets and ratings

MarketBeat data show: ^[24]

Average rating: “Buy,” with 2 Strong Buy, 21 Buy and 2 Hold ratings.
Average 12‑month price target: around $123–124 per share, with some firms going as high as the low‑ to mid‑$130s.
Several external analyses, including recent commentary cited by BiotechHealthX and Zacks, put the mean target closer to ~$127–128, implying roughly 25% upside from the low‑$100s price level seen earlier this week and an even larger premium to today’s mid‑$90s quote. ^[25]

Trefis: BSX vs IDEXX & ResMed

A new Trefis article published today compares Boston Scientific (BSX) and ResMed (RMD) with IDEXX Laboratories (IDXX) and concludes that BSX and RMD look like “smarter buys” based on growth‑adjusted valuation. ^[26]

Selected metrics from that comparison:

Price to operating income (P/OpInc):
- IDXX: 41.1x
- BSX: 39.5x
- RMD: 20.4x
Latest‑twelve‑month revenue growth:
- IDXX: 8.4%
- BSX: 21.6%
- RMD: 9.4%
3‑year average revenue growth:
- IDXX: 7.7%
- BSX: 15.6%
- RMD: 13.3%
Scale:
- BSX: $19.35 billion in LTM revenue and $3.72 billion in operating income, with an operating margin around 19%. ^[27]

The implication: BSX is growing meaningfully faster than many high‑quality peers while trading at a similar or slightly lower multiple on operating income, which supports the case for upside if execution stays on track.

6. Industry backdrop: tailwinds and headwinds

The broader medical products industry isn’t without challenges. Zacks’ industry outlook, which specifically highlights Boston Scientific as one of four names to watch, notes several macro and sector‑specific pressures: ^[28]

Tariff and cost inflation continue to squeeze margins and force supply‑chain redesigns.
Component shortages and logistics issues, while improving, still affect certain product lines.
Regulatory and reimbursement uncertainty—including evolving coverage rules and new technology pathways—adds execution risk.
Industry‑wide performance has lagged the S&P 500 over the past year, even as device makers push toward higher‑growth categories and invest heavily in AI, robotics and digital health.

Boston Scientific is positioned on the stronger side of that spectrum, with:

Broad category leadership in cardiovascular and MedSurg devices. ^[29]
A track record of accretive acquisitions (e.g., Baylis, Relievant, Elutia, Nalu) that expand its technology stack and addressable markets. ^[30]
Ongoing integration of digital and remote‑monitoring capabilities, now reinforced by today’s Epic collaboration. ^[31]

7. Key risks and what to watch next

Even with a broadly bullish long‑term setup, BSX investors should keep several risks on the radar:

Valuation risk
- At more than 50x trailing earnings and over 30x forward earnings, BSX leaves less room for execution missteps than lower‑multiple medtech peers. ^[32]
Integration and execution
- Boston Scientific is actively integrating multiple acquisitions (Relievant, Elutia, Nalu, among others). Successfully realizing synergies, avoiding distraction and maintaining innovation speed are critical to justifying its premium multiple. ^[33]
Competitive pressure in neuromodulation and structural heart
- Rivals such as Medtronic and Abbott are investing heavily in neuromodulation and electrophysiology, and Medtronic today received a separate boost from a Goldman Sachs upgrade, underscoring that competition remains intense. ^[34]
Macro and policy uncertainty
- Higher borrowing costs, shifting hospital capital budgets and changes in U.S. reimbursement policy could temper procedure growth and device adoption, particularly in elective or high‑ticket procedures. ^[35]

Upcoming catalysts

Wolfe Research Healthcare Conference replay: Management presented yesterday (Nov. 18) and emphasized innovation in electrophysiology (including FARAPULSE) and their structural‑heart portfolio. Investors will dissect those remarks for clues on growth sustainability and margin trends. ^[36]
Q4 2025 earnings (expected Feb. 4, 2026): This will be the next formal checkpoint for revenue growth, margins and guidance. ^[37]

8. Bottom line for BSX on November 19, 2025

Putting today’s moving pieces together:

Price action: BSX is down about 2.5–2.6% today and has slipped for several sessions, giving investors a rare chance to look at the name below $100 after a strong year. ^[38]
News flow:
- A bullish neuromodulation analysis from Zacks highlights sustained double‑digit growth potential in pain and DBS, reinforced by recent acquisitions and clinical data. ^[39]
- A new Epic EHR collaboration extends Boston Scientific’s reach in digital cardiology and strengthens its integration into hospital workflows. ^[40]
- 13F filings show some major funds trimming BSX exposure while others initiate or grow positions, but institutional ownership remains very high. ^[41]
Fundamentals and Street view: Q3 results beat expectations with ~20% revenue growth and raised full‑year guidance, and most analysts still see mid‑teens earnings growth and ~25% upside over the next year based on current price targets. ^[42]

For long‑term investors, today looks less like a thesis‑breaking event and more like volatility around a richly valued, high‑quality growth story. For traders, BSX’s slide back toward the mid‑$90s puts the focus on whether buyers will step in ahead of the next earnings report and the ongoing neuromodulation and digital‑health catalysts.

As always, this article is for information and education only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. Investors should consider their own objectives, risk tolerance and consult a qualified financial adviser before making trading decisions.